Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer

Respiratory Medicine

Volumn 104, Issue 3, 2010, Pages 434-439

  Kim, Young Hak ^a,b   Yoh, Kiyotaka ^a   Niho, Seiji ^a   Goto, Koichi ^a   Ohmatsu, Hironobu ^a   Kubota, Kaoru ^a   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chemotherapy; Elderly; Non small cell lung cancer; Second line; Third generation

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; NEDAPLATIN; PACLITAXEL; VINDESINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 76549136874     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.10.020     Document Type: Article

References (19)

1. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?. Lung Cancer 38 Suppl. 2 (2002) S45-S50
2. Gridelli C., Aapro M., Ardizzoni A., et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23 13 (2005) 3125-3137
3. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 2 (2002) 92-98
4. Ohe Y., Ohashi Y., Kubota K., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18 2 (2007) 317-323
5. Gridelli C., and Shepherd F.A. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128 2 (2005) 947-957
6. Gridelli C., Langer C., Maione P., Rossi A., and Schild S.E. Lung cancer in the elderly. J Clin Oncol 25 14 (2007) 1898-1907
7. Smith T.J., Penberthy L., Desch C.E., et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 13 3 (1995) 235-252
8. Brown J.S., Eraut D., Trask C., and Davison A.G. Age and the treatment of lung cancer. Thorax 51 6 (1996) 564-568
9. Earle C.C., Venditti L.N., Neumann P.J., et al. Who gets chemotherapy for metastatic lung cancer?. Chest 117 5 (2000) 1239-1246
10. Hutchins L.F., Unger J.M., Crowley J.J., Coltman Jr. C.A., and Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341 27 (1999) 2061-2067
11. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The elderly lung cancer vinorelbine Italian study group. J Natl Cancer Inst 91 1 (1999) 66-72
12. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 10 (2000) 2095-2103
13. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18 12 (2000) 2354-2362
14. Kelly K., Giarritta S., Akerley W., et al. Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest oncology trials 9509 and 9308. Proc Am Soc Clin Oncol 20 (2001) 329a
15. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst 94 3 (2002) 173-181
16. Langer C.J., Vangel J., Schiller D.P., et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol 22 (2003) 639a
17. Goto K., Nishiwaki Y., Saijo N., et al. The four-arm cooperative study (FACS) for advanced non-small cell lung cancer (NSCLC): a subgroup analysis in elderly patients. Proc Am Soc Clin Oncol 24 (2006) 7115a
18. Tsukada H., Yokoyama A., Nishiwaki Y., et al. Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207. Proc Am Soc Clin Oncol 25 (2007) 7629
19. Stinchcombe T.E., and Socinski M.A. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 Suppl. 1 (2008) 28-36